Myelodysplastic SyndromesAnemia, RefractoryAnemia, Refractory, with Excess of BlastsSyndromeLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, AcuteChromosomes, Human, Pair 5Leukemia, MyeloidAzacitidineAnemia, SideroblasticBone MarrowChromosome AberrationsKaryotypingMonosomyThalidomidePreleukemiaMyeloproliferative DisordersMyelodysplastic-Myeloproliferative DiseasesPancytopeniaAnemia, AplasticChromosomes, Human, Pair 7Cytogenetic AnalysisPrognosisBone Marrow CellsLeukemiaAcute DiseaseChromosome DeletionGranulocyte Precursor CellsTreatment OutcomeNeoplasms, Second PrimaryBone Marrow DiseasesHematopoietic Stem Cell TransplantationIron OverloadTrisomyAntimetabolites, AntineoplasticCytogeneticsErythrocyte TransfusionHematologic AgentsTransplantation, HomologousHematopoietic Stem CellsChelation TherapySurvival AnalysisAntigens, CD34ErythropoietinBlood TransfusionDown SyndromeMetabolic Syndrome XCytarabineRemission InductionMutationBlast CrisisTransplantation ConditioningBone Marrow ExaminationThrombocytopeniaHematopoiesisBlood Cell CountSurvival RateVidarabineIn Situ Hybridization, FluorescenceSweet SyndromeAnemia, MacrocyticGranulocyte Colony-Stimulating FactorDisease ProgressionHematologic DiseasesChromosomes, Human, Pair 8Antineoplastic AgentsCore Binding Factor Alpha 2 SubunitAnemiaChromosome DisordersRetrospective StudiesHaploinsufficiencyErythroid Precursor CellsKaryotypeTranslocation, GeneticChromosomes, Human, Pair 20Hematologic NeoplasmsPrimary MyelofibrosisIron Chelating AgentsHematinicsFlow CytometryLeukemia, Myelomonocytic, AcuteErythroid CellsBone Marrow TransplantationErythroblastsRisk FactorsDNA Modification MethylasesImmunophenotypingHemoglobinuria, ParoxysmalAntilymphocyte SerumBusulfanFatal OutcomeIsochromosomesHLA-DR Serological SubtypesRecurrenceMyeloid Progenitor CellsDNA Mutational AnalysisErythropoiesisRibonucleoprotein, U2 Small NuclearAntineoplastic Combined Chemotherapy ProtocolsThrombocytosis